Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
58/435
Matches for
“antiviral agents”
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
…Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
…New direct-acting antiviral agent (DAA) combination therapy has not yet been…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
…They exerted an impact on immunosuppressive and antiviral therapies.
-
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
### Background Genotype 1b is the most common HCV genotype worldwide, accounting for…
-
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
In therapy with standard interferon and ribavirin, five independent risk factors (RF…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
…assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC…
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
…target the viral trigger using antiviral therapy [pegylated interferon plus ribavirin (PEG…
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
### Background The efficacy of a maintenance therapy in non-responder patients with…
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
…successful treatment with telaprevir-based antiviral regimens. We performed a retrospective analysis…
-
American Association for the Study of the Liver
-
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
…features, HCV virologic response to antiviral therapy, and HIV infection characteristics were…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
…associated with virological response to antiviral therapy. The aim of this study…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
…hepatitis C patients eligible for antiviral therapy. ### Patients And Methods A retrospective…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Review
It is estimated that hepatitis C virus (HCV) infects chronically about 160…
-
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Hepatitis C virus (HCV) infection is a major cause of chronic liver…
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Key publication
A liver fibrosis index was recently prospectively validated in a cross-sectional…
-
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
…Here, we aimed to assess the effect of antiviral treatment on non…
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
…This study assessed the prevalence, characteristics, and outcomes of antiviral therapy in…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
…One hundred seventy patients>or=65 yr received antiviral therapy. A sustained…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
### Aim We evaluated the association between two medications that alter bioavailable androgen…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
### Background Due to common routes of transmission, HIV and HBV are frequently…
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. Review
…to prognosticate treatment response to antiviral therapy. It has also been shown…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
The aim was to assess the utility of FibroTest-ActiTest (FT-AT…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Changes of non-invasive markers and FibroScan values during HCV treatment.
The recent advent of non-invasive methods for assessment of fibrosis allows…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Liver fibrosis and activity indexes were validated in patients infected by hepatitis…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication
### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…
-
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.
### Background Liver biopsy is the reference standard for assessing liver fibrosis and…
-
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
Showing the full result list. The page is server-rendered and not paginated.